NEWCaplight raises a $16M Series A, led by BlackRock and Fin Capital →
Skip to main content
Caplight Logo









Jiajin Biopharmaceutical (Shanghai) Co., Ltd.

Private
ShanghaiHealthcare & Life Sciences

Last Round

Series B++

Jun 5, 2026

Total Funding Raised

$6.29M

Company Overview

Jiajin Biopharmaceutical (Shanghai) Co., Ltd. is a biotechnology company that specializes in antibody-small nucleic acid coupled drugs and brain-delivery platforms for the treatment of genetic and neurodegenerative diseases.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Drug Discovery, Precision Medicine

Business Model

B2B

Customer Profile

Services & Consulting

AI Layer

Non-AI

Keywords

drug delivery platformblood-brain barrierantibody-small nucleic acid conjugateAOCneurodegenerative diseasebrain-entry peptideneuromuscular diseaseCNS therapeuticsbiotech drug deliverypeptide shuttledrug licensingtargeted drug deliverybiotech R&D

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

Jiajin Biopharmaceutical (Shanghai) Co., Ltd. Comps

Public and private peers based on sector, stage, and business model.

Jiajin Biopharmaceutical (Shanghai) Co., Ltd. comps — public and private peers by sector, stage, and business model
CompanyStatusEst. ValuationRev Multiple
OpenAIPrivate$86.0B~40x
CoherePrivate$5.0B--
Competitor 1Public$XX.XBXXx
Competitor 2Public$XX.XBXXx

View Full Comps Set

Access detailed peer comparisons, multiples, and valuation benchmarks.

Jiajin Biopharmaceutical (Shanghai) Co., Ltd. Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
Series B++Jun 5, 2026
Series B ExtensionDec 26, 2025
Series BAug 19, 2025
Series A++Apr 3, 2025
Series A ExtensionNov 8, 2024
Series A
Jun 15, 2024

Jiajin Biopharmaceutical (Shanghai) Co., Ltd. Investors

Notable investors and investment history

Jiajin Biopharmaceutical (Shanghai) Co., Ltd. investors
InvestorRounds
Shanghai Science & Technology Venture Capital (Group)Series B++
Legend CapitalSeries B Extension, Series B++
Frees FundSeries B++, Angel
Sunshine Insurance GroupSeries B++, Series B
MPCSeries B++, Angel
Lilly Asia VenturesSeries B++
Qingsong CapitalSeries B++

Jiajin Biopharmaceutical (Shanghai) Co., Ltd. Filings

SEC and related filings with document metadata.

Data table
TypedDateAmount OfferedAmount SoldFillingPagesDownload
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation

Jiajin Biopharmaceutical (Shanghai) Co., Ltd. Filings

SEC and related filings with document metadata.

Frequently Asked Questions

Common questions about Jiajin Biopharmaceutical (Shanghai) Co., Ltd.'s valuation, stock price, and market status.

Firmographic Details

HeadquartersShanghai
Year Founded2021
Last FundingJun 5, 2026

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.